Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Karin Aase is active.

Publication


Featured researches published by Karin Aase.


Nature Cell Biology | 2000

PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor.

Xuri Li; Annica Ponten; Karin Aase; Linda Karlsson; Alexandra Abramsson; Marko Uutela; Gudrun Bäckström; Mats Hellström; Hans Boström; Hong Li; Philippe Soriano; Christer Betsholtz; Carl-Henrik Heldin; Kari Alitalo; Arne Östman; Ulf Eriksson

Platelet-derived growth factors (PDGFs) are important in many types of mesenchymal cell. Here we identify a new PDGF, PDGF-C, which binds to and activates the PDGF α-receptor. PDGF-C is activated by proteolysis and induces proliferation of fibroblasts when overexpressed in transgenic mice. In situ hybridization analysis in the murine embryonic kidney shows preferential expression of PDGF-C messenger RNA in the metanephric mesenchyme during epithelial conversion. Analysis of kidneys lacking the PDGF α-receptor shows selective loss of mesenchymal cells adjacent to sites of expression of PDGF-C mRNA; this is not found in kidneys from animals lacking PDGF-A or both PDGF-A and PDGF-B, indicating that PDGF-C may have a unique function.


American Journal of Pathology | 1998

Vascular Endothelial Growth Factors VEGF-B and VEGF-C Are Expressed in Human Tumors

Petri Salven; Athina Lymboussaki; Päivi Heikkilä; Hilkka Jääskela-Saari; Bernd Enholm; Karin Aase; Gabriel von Euler; Ulf Eriksson; Kari Alitalo; Heikki Joensuu

The growth of solid tumors is dependent on angiogenesis, the formation of new blood vessels. Vascular endothelial growth factor (VEGF) is a secreted endothelial-cell-specific mitogen. We have recently characterized two novel endothelial growth factors with structural homology to VEGF and named them VEGF-B and VEGF-C. To further define the roles of VEGF-B and VEGF-C, we have studied their expression in a variety of human tumors, both malignant and benign. VEGF-B mRNA was detected in most of the tumor samples studied, and the mRNA and the protein product were localized to tumor cells. Endothelial cells of tumor vessels were also immunoreactive for VEGF-B, probably representing the binding sites of the VEGF-B polypeptide secreted by adjacent tumor cells. VEGF-C mRNA was detected in approximately one-half of the cancers analyzed. Via in situ hybridization, VEGF-C mRNA was also localized to tumor cells. All lymphomas studied contained low levels of VEGF-C mRNA, possibly reflecting the cell-specific pattern of expression of the VEGF-C gene in the corresponding normal cells. The expression of VEGF-C is associated with the development of lymphatic vessels, and VEGF-C could be an important factor regulating the mutual paracrine relationships between tumor cells and lymphatic endothelial cells. Furthermore, VEGF-C and VEGF-B can, similarly to VEGF, be involved in tumor angiogenesis.


Circulation | 2001

Vascular Endothelial Growth Factor-B–Deficient Mice Display an Atrial Conduction Defect

Karin Aase; Gabriel von Euler; Xuri Li; Annica Ponten; Peter Thorén; Renhai Cao; Yihai Cao; Birgitta Olofsson; Samuel Gebre-Medhin; Milos Pekny; Kari Alitalo; Christer Betsholtz; Ulf J. Eriksson

Background—Vascular endothelial growth factors (VEGFs) and their receptors are essential regulators of vasculogenesis and angiogenesis in both embryos and adults. One of the factors with a still unknown physiological function is VEGF-B, which is expressed in many tissues, including the heart. Methods and Results—Mice carrying a targeted deletion in the VEGF-B gene were developed. In VEGF-B−/− animals, no gross abnormalities were observed in organs that normally show high expression of VEGF-B, such as the heart, muscle, and kidney. Analysis of heart function by ECG showed that adult VEGF-B−/− mice have an atrial conduction abnormality characterized by a prolonged PQ interval. VEGF- or basic fibroblast growth factor–induced corneal angiogenesis was similar in normal and VEGF-B−/− mice. Conclusions—VEGF-B seems to be required for normal heart function in adult animals but is not required for proper development of the cardiovascular system either during development or for angiogenesis in adults.


American Journal of Pathology | 2003

Transgenic overexpression of platelet-derived growth factor-C in the mouse heart induces cardiac fibrosis, hypertrophy, and dilated cardiomyopathy.

Annica Ponten; Xuri Li; Peter Thorén; Karin Aase; Tobias Sjöblom; Arne Östman; Ulf Eriksson

The platelet-derived growth factors are implicated in development of fibrotic reactions and disease in several organs. We have overexpressed platelet-derived growth factor-C in the heart using the alpha-myosin heavy chain promoter and created a transgenic mouse that exhibits cardiac fibrosis followed by hypertrophy with sex-dependent phenotypes. The transgenic mice developed several pathological changes including cardiac fibroblast proliferation and deposition of collagen, hypertrophy, vascular defects, and the presence of Anitschkow cells in the adult myocardium. Male mice developed a hypertrophic phenotype, whereas female mice were more severely affected and developed dilated cardiomyopathy, leading to heart failure and sudden death. The vascular defects initially included dilation of microvessels and vascular leakage. Subsequently, a marked loss of microvessels, formation of large vascular sac-like structures, and an increased density of smooth muscle-coated vessels were observed in the myocardium. In part, the observed vascular changes may be because of an up-regulation of vascular endothelial growth factor in cardiac fibroblasts of the transgenic hearts. This unique animal model reveals that a potent mitogen for cardiac fibroblasts result in an expansion of the interstitium that induce a secondary sex-dependent hypertrophic response in the cardiomyocytes.


Developmental Dynamics | 1999

Localization of VEGF‐B in the mouse embryo suggests a paracrine role of the growth factor in the developing vasculature

Karin Aase; Athina Lymboussaki; Arja Kaipainen; Birgitta Olofsson; Kari Alitalo; Ulf Eriksson

Vascular endothelial growth factor B (VEGF‐B) is structurally closely related to VEGF and binds one of its receptors, VEGFR‐1. In situ hybridization and immunohistochemistry were used to localize VEGF‐B mRNA and protein in embryonic mouse tissues. In 8.5–17.5 day embryos, VEGF‐B was most prominently expressed in the developing myocardium, but not in the cardiac cushion tissue. The strong expression in the heart persisted at later developmental stages, while weaker signals were obtained from several other tissues, including developing muscle, bone, pancreas, adrenal gland, and from the smooth muscle cell layer of several larger vessels, but not from endothelial cells. VEGF‐B is likely to act in a paracrine fashion, as its receptor is almost exclusively present in endothelial cells. VEGF‐B may have a role in vascularization of the heart, skeletal muscles and developing bones, and in paracrine interactions between endothelial and surrounding muscle cells. Dev Dyn 1999;215:12–25.


Mechanisms of Development | 2002

Expression analysis of PDGF-C in adult and developing mouse tissues.

Karin Aase; Alexandra Abramsson; Linda Karlsson; Christer Betsholtz; Ulf Eriksson

There are four members of the platelet-derived growth factor (PDGF) family; PDGF-A, PDGF-B, PDGF-C and PDGF-D. Their biological effects are mediated via two tyrosine kinase receptors, PDGFR-alpha and PDGFR-beta, and PDGF-mediated signaling is critical for development of many organ systems. Analysis in adult tissues showed that PDGF-C was mainly expressed in kidney, testis, liver, heart and brain. During development, PDGF-C expression was widespread and dynamic, and found in somites and their derivatives, in kidney, lung, brain, and in several other tissues, particularly at sites of developing epidermal openings. PDGF-C may therefore have unique functions during tissue development and maintenance.


Proceedings of the National Academy of Sciences of the United States of America | 1998

Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells

Birgitta Olofsson; Eija Korpelainen; Michael S. Pepper; Stefano J. Mandriota; Karin Aase; Vijay Kumar; Yuji Gunji; Michael Jeltsch; Masabumi Shibuya; Kari Alitalo; Ulf J. Eriksson


Archive | 1999

PLATELET-DERIVED GROWTH FACTOR C, DNA CODING THEREFOR, AND USES THEREOF

Ulf Eriksson; Karin Aase; Xuri Li; Annica Ponten; Marko Uutela; Kari Alitalo; Arne Oestman; Carl-Henrik Heldin


Archive | 1999

Platelet-derived growth factor D

Ulf Eriksson; Karin Aase; Xuri Lee; Annica Ponten; Marko Uutela; Kari Alitalo; Arne Oestman; Carl-Henrik Heldin


Archive | 1998

Transgenic animal with recombinant vascular endothelial growth factor B (VEGF-B DNA) and uses thereof

Gabriel von Euler; Karin Aase; Christer Betsholtz; Ulf Eriksson; Milos Pekny; Samuel Gebre-Medhin; Xuri Li

Collaboration


Dive into the Karin Aase's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Xuri Li

Sun Yat-sen University

View shared research outputs
Top Co-Authors

Avatar

Annica Ponten

Ludwig Institute for Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Carl-Henrik Heldin

Ludwig Institute for Cancer Research

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Arne Oestman

Ludwig Institute for Cancer Research

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gabriel von Euler

Ludwig Institute for Cancer Research

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge